


TRANSMITTAL

FORM



Application Number: 10/676,725
 Filing Date: October 1, 2003
 First Named Inventor: Michael G. Rosenblum
 Art Unit: 1615
 Examiner Name: Unknown
 Attorney Docket Number: CLFR:029USD1

Total Number of Pages in this Submission:

ENCLOSURES (check all that apply)

- | | | |
|--|---|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement
<input checked="" type="checkbox"/> Form PTO-1449
<input checked="" type="checkbox"/> References <u>B8-B42, C18-C185</u>
<input type="checkbox"/> Certified Copy of Priority Documents
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53
<input type="checkbox"/> Declaration(s) _____
<input type="checkbox"/> Copy of Notice of Missing Parts | <input type="checkbox"/> Drawings(s) _____
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address
<input type="checkbox"/> Statement under 37 CFR §3.73(b)
<input type="checkbox"/> Designation of Patent Practitioners
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number CD(s) _____
<input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below)
<input type="checkbox"/> Check in the amount of \$
<input checked="" type="checkbox"/> Authorized to be charged to deposit account if check insufficient or inadvertently omitted
Deposit account number: <u>50-1212/CLFR:029USD1</u>
<input type="checkbox"/> Sequence Statement
<input type="checkbox"/> Paper Copy of Sequence Listing
<input type="checkbox"/> Computer Readable Form (CRF)
<input checked="" type="checkbox"/> Postcard
<input type="checkbox"/> _____
<input type="checkbox"/> _____ |
|--|---|--|

Remarks:

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Fulbright & Jaworski, L.L.P.	Customer Number	32425
Signature			
Printed Name	David L. Parker	Reg. No.	32,165
Date	May 27, 2005		

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or Printed Name	David L. Parker	Date	May 27, 2005

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Michael Rosenblum

Serial No.: 10/676,725

Filed: October 1, 2003


For: NOVEL ANTIBODY DELIVERY
SYSTEM FOR BIOLOGICAL RESPONSE
MODIFIERS



Group Art Unit: 1615

Examiner: Unknown

Atty. Dkt. No.: CLFR:029USD1

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
May 27, 2005	
Date	David L. Parker

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner. Copies of cited U.S. patents, U. S. patent application publications and co-pending U.S. patent applications have not been enclosed subject to the waiver regarding the requirement

under 37 C.F.R. §1.98(a)(2)(i) stated in the Official Gazette Notice dated August 5, 2003 regarding patent applications filed on or after June 30, 2003.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/CLFR:029USD1.

This application is a divisional application of Serial No. 07/348,237, filed May 5, 1989; Serial No. 07/951,357, filed September 25, 1992; Serial No. 08/119,505, filed September 10, 1993; and Serial No. 08/251,574, filed May 31, 1994 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) only copies of those documents not previously cited and submitted to the Patent and Trademark Office in prior application Serial No. 07/348,237 are enclosed for the convenience of the Examiner.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,

A handwritten signature in black ink, appearing to be "D. Parker", written over the words "Respectfully submitted,".

David L. Parker
Reg. No. 32,165
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: May 27, 2005

Form PTO-1449 (modified)

Atty. Docket No.
CLFR:029USD1Serial No.
10/676,725

List of Patents and Publications for Applicant's

Applicant
Michael Rosenblum

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
October 1, 2003Group:
1615U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 2Other Art
See Page 4

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A8	2004/0013691	1/22/04	Rosenblum	424	234.1	6/12/03
	A9	4,263,279	4/21/81	Sela <i>et al.</i>	424	85	7/24/78
	A10	4,414,148	11/8/83	Jansen <i>et al.</i>	530	391.9	4/14/82
	A11	4,522,918	6/11/85	Schlom <i>et al.</i>	435	68	12/15/81
	A12	4,590,071	5/20/86	Scannon <i>et al.</i>	424	85	11/25/84
	A13	4,677,064	6/30/87	Mark <i>et al.</i>	435	68	5/2/85
	A14	4,801,578	6/4/84	Monsigny <i>et al.</i>	514	8	6/4/84
	A15	4,831,122	5/16/89	Buchsbaum <i>et al.</i>	530	391.3	1/9/86
	A16	4,863,726	11/5/89	Stevens <i>et al.</i>	424	85.2	12/9/87
	A17	4,888,415	12/19/89	Lambert <i>et al.</i>	530	390	3/7/88
	A18	4,894,225	1/16/90	Zimmerman	424	85.1	3/2/87
	A19	4,894,227	1/16/90	Stevens <i>et al.</i>	424	85.2	5/29/87
	A20	4,894,443	1/16/90	Greenfield <i>et al.</i>	530	388	11/7/84
	A21	4,946,778	8/7/90	Landner <i>et al.</i>	435	69.6	1/19/89
	A22	4,962,188	10/9/90	Frankel	530	389	9/30/86
	A23	4,963,354	10/16/90	Shepard <i>et al.</i>	424	85.1	1/21/87
	A24	4,980,457	12/25/90	Jansen <i>et al.</i>	530	391	11/11/87
	A25	5,017,371	5/21/91	Cummins	424	85.6	1/6/88
	A26	5,019,368	5/28/91	Epstein <i>et al.</i>	424	1.1	2/23/89
	A27	5,134,075	7/28/92	Hellstrom <i>et al.</i>	530	387.3	2/17/89
	A28	5,359,046	10/25/94	Capon <i>et al.</i>	536	23.4	12/9/92
	A29	5,624,827	4/29/97	Rosenblum and Beattie	435	91.5	10/21/94
	A30	5,631,348	5/20/97	Rosenblum <i>et al.</i>	530	370	6/06/94

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 4</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A31	5,720,954	2/24/98	Hudziak <i>et al.</i>	424	130.1	5/23/95
	A32	5,744,580	4/28/98	Better <i>et al.</i>	530	377	6/7/95
	A33	5,770,195	6/23/98	Hudziak <i>et al.</i>	424	130.1	5/23/95
	A34	5,837,491	11/17/98	Better <i>et al.</i>	435	69.1	5/12/94
	A35	6,084,073	7/4/00	Piatak, Jr.	530	370	6/5/95
	A36	6,099,842	8/8/00	Pastan <i>et al.</i>	424	183.1	12/3/90
	A37	6,214,974	4/10/01	Rosenblum and Donato	530	391.9	3/27/95
	A38	6,306,626	10/23/01	Rosenblum and Donato	435	70.21	2/07/94
	A39	6,599,505	7/29/03	Rosenblum	424	134.1	2/19/98
	A40	6,669,938	12/30/03	Rosenblum <i>et al.</i>	424	183.1	11/24/93
	A41	6,750,329	6/15/04	Rosenblum <i>et al.</i>	530	391.7	5/31/94
	A42	RE37,642	12/04/01	Rosenblum <i>et al.</i>	530	370	5/20/99
	A43	10/926,731		Rosenblum			8/26/04
	A44	2003/0073163	4/17/03	Fernandez <i>et al.</i>	435	69.1	11/14/01
	A45	2003/0086919	5/08/03	Rosenblum and Liu	424	94.63	7/17/02
	A46	2003/0134302	7/17/03	Fernandez <i>et al.</i>	435	6	8/01/02
	A47	2003/0176331	9/18/03	Rosenblum and Cheung	514	12	2/12/02
	A48	2003/0186384	10/02/03	Barth <i>et al.</i>	435	69.5	4/20/01
	A49	2004/0009477	1/15/04	Fernandez <i>et al.</i>	435	6	11/21/01

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B8	EP 0160446	4/15/85	Europe			English

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 4</i>	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B9	EP 0222360	5/20/87	Europe			English
	B10	EP 0305967	3/8/89	Europe			None
	B11	EP 0336631	10/11/89	Europe			English
	B12	EP 0350230	1/10/90	Europe			English
	B13	EP 0396387	11/7/90	Europe			English
	B14	GB 2148299	5/30/85	United Kingdom			English
	B15	JP 190200	8/20/87	Japan			Partial
	B16	JP 62209098	12/6/86	Japan			Abstract
	B17	JP 86121	7/13/81	Japan			Partial
	B18	WO 85/00974	8/31/84	WIPO			English
	B19	WO 86/02945	5/22/86	WIPO			English
	B20	WO 86/05098	7/8/85	WIPO			English
	B21	WO 87/00056	6/6/86	WIPO			English
	B22	WO 88/09343	12/1/88	WIPO			Abstract
	B23	WO 89/00999	2/9/89	PCT			English
	B24	WO 90/00405	1/25/90	WIPO			English
	B25	WO 91/16071	10/31/91	WIPO			English
	B26	WO 94/26910	11/24/94	WIPO			English
	B27	WO 97/22364	6/26/97	WIPO			English
	B28	WO 97/46259	12/11/97	WIPO			English
	B29	WO 99/49059	9/30/99	WIPO			English
	B30	WO 99/40198	8/12/99	WIPO			English
	B31	WO 99/45128	9/10/99	WIPO			English

25527756.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Michael Rosenblum	
	Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 4</i>

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B32	WO 99/51620	10/14/99	WIPO			English
	B33	WO 99/51766	10/14/99	WIPO			English
	B34	WO 03/002598	1/09/03	WIPO			English
	B35	WO 00/34317	6/15/00	WIPO			English
	B36	AU A13017/88	9/15/88	Australia			English
	B37	AU A21725/88	3/23/89	Australia			English
	B38	AU A30753/89	8/31/89	Australia			English
	B39	AU B79527/87	4/14/88	Australia			English
	B40	AU B82047/87	6/9/88	Australia			English
	B41	EP 0118365	3/2/84	Europe			English
	B42	EP 0150126	7/31/85	Europe			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C18	Blink <i>et al.</i> , "Curtin Conference: Perforin-dependent nuclear targeting of granzymes: A central role in the nuclear events of granule-exocytosis-mediated apoptosis?," <i>Immunology and Cell Biology</i> , 77:206-215, 1999.
	C19	Bolognesi <i>et al.</i> , "In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins," <i>Br. J. Haematol.</i> , 110(2):351-361, 2000.
	C20	Brunet <i>et al.</i> , "The inducible cytotoxic T-lymphocyte-associated gene transcript CTLA-1 sequence and gene localization to mouse chromosome 14," <i>Nature</i> , 322(6076):268-271, 1986.
	C21	Bumol <i>et al.</i> , "Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans," <i>J. Biol. Chem.</i> , 259:12733-12741, 1984.

25527756.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 4</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C22	Chan <i>et al.</i> , "Comparison of gallium-67 versus indium-111 monoclonal antibody (96.5, ZME-018) in detection of human melanoma in athymic mice," <i>J. Nucl. Med.</i> , 28:1441-1446, 1987.
	C23	Chaudhary <i>et al.</i> , "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," <i>Nature</i> , 339:394-397, 1989.
	C24	Collen <i>et al.</i> , "Recombinant staphylokinase variants with altered immunoreactivity," <i>Circulation</i> , 94:197-206, 1996.
	C25	Crosby <i>et al.</i> , "A complex of serine protease gene expressed preferentially in cytotoxic T-lymphocytes is closely linked to the T-cell receptor alpha- and delta-chain genes on mouse chromosome 14," <i>Genomics</i> , 6(2):252-259, 1990.
	C26	Dahl <i>et al.</i> , "Isolation of a cDNA clone encoding a novel form of granzyme B from human NK cells and mapping to chromosome 14," <i>Hum. Genet.</i> , 84(5):465-470, 1990.
	C27	DeLand <i>et al.</i> , "A perspective of monoclonal antibodies: past, present, and future," <i>Seminars in Nuc. Med.</i> , 19(3):158-165.
	C28	Dermer, "Another anniversary for the war on cancer," <i>Bio/technology</i> , 12:320, 1994.
	C29	Dillman, "Monoclonal antibodies for treating cancer," <i>Ann. Intern. Med.</i> , 111:592-603, 1989.
	C30	Dumontet, "[Immunotherapy and cancer: the role of monoclonal antibodies]," <i>J. Chir. (Paris)</i> , 126:682-686, 1989.
	C31	Engert <i>et al.</i> , "Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins," <i>Leuk. Res.</i> , 15:1079-1086, 1991.
	C32	Falasca <i>et al.</i> , "Properties of the ribosome-inactivating proteins gelonin, Momordica charantia inhibitor, and dianthins," <i>Biochem. J.</i> , 207:505-509, 1982.
	C33	Fiers <i>et al.</i> , "Tumor necrosis factor: a potential anti tumor agent," <i>J. Interferon Res.</i> , 7:627-634, 1987.
	C34	Frankel <i>et al.</i> , "Prospects for immunotoxin therapy in cancer," <i>Ann. Rev. Med.</i> , 37:125-142, 1986.
	C35	Freshney, "Culture of animal cells, a manual of basic technique," Alan R. Liss, Inc, 1983.
	C36	Friedman <i>et al.</i> , "BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells," <i>Cancer Res.</i> , 53:334-339, 1993.

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 4</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C37	Frontiera <i>et al.</i> , "Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma," <i>Clin. Nucl. Med.</i> , 14:357-366, 1989.
	C38	Gallego <i>et al.</i> , "Preparation of four daunomycin-monoclonal antibody 791T/36 conjugates with anti-tumour activity," <i>Int. J. Cancer</i> , 33:737-744, 1984.
	C39	Gase <i>et al.</i> , "Functional significance of NH ₂ - and COOH- terminal regions of staphylokinase in plasminogen activation," <i>Thrombosis and Haemostasis</i> , 76(5):755-760, 1996.
	C40	GenBank Accession Number L12243.
	C41	Giacomini <i>et al.</i> , "Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells," <i>J. Immunol.</i> , 133(3):1649-1655, 1984.
	C42	Gillies <i>et al.</i> , "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <i>Hum. Antibodies Hybridomas.</i> , 1:47-54, 1990.
	C43	Gould <i>et al.</i> , "Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies," <i>J. Natl. Cancer Inst.</i> , 81:775-781, 1989.
	C44	Green <i>et al.</i> , "Monoclonal antibody therapy for solid tumors," <i>Cancer Treat Rev.</i> , 26:269-286, 2000.
	C45	Greiner <i>et al.</i> , "Differential effects of recombinant human leukocyte interferons on cell surface antigen expression," <i>Cancer Res.</i> , 46:4984-4990, 1986.
	C46	Greiner <i>et al.</i> , "Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment," <i>Cancer Res.</i> , 44:3208-3214, 1984.
	C47	Haddad <i>et al.</i> , "Structural organization of the hCTLA-1 gene encoding human granzyme B," <i>Gene</i> , 87(2):265-271, 1990.
	C48	Hamburger and Salmon, "Primary bioassay of human tumor stem cells," <i>Science</i> , 197:461-463, 1977.
	C49	Hann <i>et al.</i> , "Building 'validated' mouse models of human cancer," <i>Curr. Opin. Cell Biol.</i> , 13:778-784, 2001.

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C50	Hanson <i>et al.</i> , "A cluster of hematopoietic serine protease genes is found on the same chromosomal band as the human $\alpha\delta$ T-cell receptor locus," <i>Proc. Natl. Acad. Sci., USA</i> , 87:960-963, 1990.
	C51	Harlow <i>et al.</i> , <i>Antibodies: A laboratory Manual</i> , Cold Spring Harbor Press, pp. 72-77, 92-97, 128-135, and 141-157, 1988.
	C52	Harper <i>et al.</i> , "Proximity of the CTLA-1 serine esterase and Tcr alpha loci in mouse and man," <i>Immunogenetics</i> , 28(6):439-444, 1988.
	C53	Henkart, "Mechanism of Lymphocyte-mediated Cytotoxicity," <i>Ann. Rev. Immunol.</i> , 3:31-58, 1985.
	C54	Hertler <i>et al.</i> , "A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia," <i>J. Biol. Response Mod.</i> , 7:97-113, 1987.
	C55	Hoogenboom <i>et al.</i> , "Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule," <i>Biochim Biophys Acta.</i> , 1096:345-354, 1991.
	C56	Huston <i>et al.</i> , "Single-chain immunotechnology of Fv analogues and fusion proteins," in <i>Immunotechnology</i> , Gosling and Reen (eds), pg. 47-60, 1993.
	C57	Imai <i>et al.</i> , "[Current status of monoclonal antibodies to human melanoma and its application]," <i>Gan To Kagaku Ryoho.</i> , 10:852-860, 1983 (abstract in English).
	C58	Imai <i>et al.</i> , "Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melanoma cells: relationship to susceptibility to immune lysis mediated by monoclonal antibodies," <i>J. Immunol.</i> , 127(2):505-509, 1981.
	C59	Johnson, "Review: Noncaspase proteases in apoptosis," <i>Leukemia</i> , 14:1695-1703, 2000.
	C60	Juhl <i>et al.</i> , "New approaches in gastric cancer research: I. Monoclonal antibodies in diagnosis and therapy," <i>Hepatogastroenterol.</i> 36:27-32, 1989.
	C61	Julius <i>et al.</i> , "Induction of resting B cells to DNA synthesis by soluble monoclonal anti-immunoglobulin," <i>Eur. J. Immunol.</i> , 14:753-757, 1984.
	C62	Kagawa <i>et al.</i> , "A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax," <i>Gene Therapy</i> , 7:75-79, 2000.

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C63	Kagawa <i>et al.</i> , "Antitumor Effect of Adenovirus-mediated Bax Gene Transfer on p53-sensitive and p53-resistant Cancer Lines," <i>Cancer Research</i> , 60:1157-1161, 2000.
	C64	Kam <i>et al.</i> , "Review: Granzymes (lymphocyte serine proteases): characterization with natural and synthetic substrates and inhibitors," <i>Biochimica et Biophysica Acta</i> , 1477:307-323, 2000.
	C65	Kaneta <i>et al.</i> , "Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo," <i>Jpn J. Cancer Res.</i> , 89(5):583-588, 1998.
	C66	Kim and Weaver, "Construction of a recombinant expression plasmid encoding a staphylococcal protein A-ricin A fusion protein," <i>Gene</i> , 68:315-321, 1988.
	C67	Kimmel <i>et al.</i> , "In vitro drug sensitivity testing in human gliomas," <i>J. Neurosurg.</i> 66:161-171, 1987.
	C68	Kipriyanov <i>et al.</i> , "Recombinant single-chain Fv fragments carrying c-terminal cysteine residues: production of bivalent and biotinylated miniantibodies," <i>Molecular Immunology</i> , 31:1047-1058, 1994.
	C69	Kirkwood <i>et al.</i> , "Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018)," <i>J. Clin. Oncol.</i> , 5:1247-1255, 1987.
	C70	Klein <i>et al.</i> , "Genomic organization and chromosomal assignment for a serine protease gene (CSPB) expressed by human cytotoxic lymphocytes," <i>Genomics</i> , 5(1):110-117, 1989.
	C71	Koizumi <i>et al.</i> , "Immunoscintigraphy and pharmacokinetics of indium-111-labeled ZME-018 monoclonal antibody in patients with malignant melanoma," <i>Japanese J of Cancer Res</i> , 79:973-981, 1988.
	C72	Kovarik <i>et al.</i> , "Biochemical and histochemical characteristic of target antigen detected by monoclonal antibody HBCa-12 against a membrane component of human mammary carcinoma cell line," <i>Neoplasma</i> , 31(6):625-630, 1984.
	C73	Kudlicki <i>et al.</i> , "Elongation and folding of nascent ricin chains as peptidyl-rRNA on ribosomes: the effect of amino acid deletions on these processes," <i>J. Mol. Biol.</i> , 252:203-212, 1995.
	C74	Kufe <i>et al.</i> , "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant vs. benign breast tumors," <i>Hybridoma</i> , 3(3):223-232, 1984.

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 4</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C75	Kung et al., "A mouse IgM allotypic determinant (Igh-6.5) recognized by a monoclonal rat antibody," <i>J. Immunol.</i> 127:873-876, 1981.
	C76	Kurucz et al., "A bacterial expressed single-chain Fv construct from the 2B4 T-cell receptor," <i>Proc Natl Acad Sci USA</i> ; 90: 3830-3834, 1993.
	C77	Lambert et al., "Immunotoxins containing single chain ribosome-inactivating proteins," in <i>Immunotoxins</i> , Frankel ed., pg 175-209, 1988.
	C78	Lambert et al., "Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins," <i>J. Biol. Chem.</i> , 260(22):12035-12041, 1985.
	C79	Lazar et al., "Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities," <i>Mol. Cell. Biol.</i> , 8:1247-1252, 1988.
	C80	Leibovitz et al., "A hypo-osmotic medium to disaggregate tumor cell clumps into viable and clonogenic single cells for the human tumor stem cell clonogenic assay," <i>Int. J. Cell Cloning</i> , 1:478-485, 1983.
	C81	Levy et al., "Retroviral transfer and expression of a humanized, red-shifted green fluorescent protein gene into human tumor cells," <i>Nat. Biotechnol.</i> , 14:610-614, 1996.
	C82	Lewis and Crowe, "Generation of humanized monoclonal antibodies by 'best' fit framework selection and recombinant polymerase chain reaction," <i>Year Immunol.</i> , 7:110-118, 1993.
	C83	Lin et al., "Chromosomal localization of two human serine protease genes to region 14q11.2---q12 by in situ hybridization," <i>Cytogenet Cell Genet.</i> , 53(2-3):169-171, 1990.
	C84	Lubin et al., "Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis," <i>J. Biol. Chem.</i> , 272(48):30191-30195, 1997.
	C85	Macey et al., "Uptake of Indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma," <i>Am J of Physiologic Imaging</i> ; 3:1-6, 1988.
	C86	Mazurier et al., "Rapid analysis and efficient selection of human transduced primitive hematopoietic cells using the humanized S65T green fluorescent protein," <i>Gene Ther.</i> , 5:556-562, 1998.

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 4</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C87	McCartney <i>et al.</i> , "Engineering disulfide-linked singl-chain Fv dimers [(sFv') ₂] with improved solution and targeting properties: anti-digoxin 26-10 (sFv') ₂ and anti-c-erbB-2 741F8 (sFv') ₂ made by protein folding and bonded through C-terminal cysteinyl peptides," <i>Protein Engineering</i> ; 8:301-314, 1994.
	C88	Miescher-Granger <i>et al.</i> , "Biological activities of human recombinant interferon alpha/beta targeted by anti-Epstein-Barr virus monoclonal antibodies," <i>FEBS Lett.</i> , 179:29-33, 1985.
	C89	Mihich, "Future perspectives for biological response modifiers: a viewpoint," <i>Sem Oncol.</i> , 13:234-254, 1986.
	C90	Montanaro <i>et al.</i> , "A metalloproteinase associated with gelonin, a ribosome inactivating protein," <i>Ital. J. Biochem.</i> , pg 1-10, 1984.
	C91	Moola <i>et al.</i> , "Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes," <i>Biochem J.</i> , 302(Pt 3):921-7, 1994.
	C92	Morris and Wool, "Determination by systematic deletion of the amino acids essential for catlysis by ricin A chain," <i>Proc. Natl. Acad. Sci. USA</i> , 89:4869-4873, 1992.
	C93	Motyka <i>et al.</i> , "Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis," <i>Cell</i> , 103(3):491-500, 2000.
	C94	Mujoo <i>et al.</i> , "Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin," <i>Cancer Immunology, Immunotherapy</i> ; 40:339-345, 1995.
	C95	Mujoo <i>et al.</i> , "Pharmacology and therapeutic studies with ZME-gelonin immunotoxin," <i>Proc. Am Assoc. Cancer Res</i> , 32:266, #1580, 1991.
	C96	Muldoon <i>et al.</i> , "Tracking and quantitation of retroviral-mediated transfer using a completely humanized, red-shifted green fluorescent protein gene," <i>Biotechniques</i> , 22:162-167, 1997.
	C97	Munishkin and Wool, "Systematic deletion analysis of ricin A-chain function," <i>J Biol. Chem.</i> , 270:30581-30587, 1995.
	C98	Murray <i>et al.</i> , "Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018" <i>J. Nuclear Med.</i> , 28:25-33, 1987.

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 4</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C99	Murray <i>et al.</i> , "Differential in vitro effects of alpha recombinant interferon and gamma recombinant interferon on the expression of melanoma-associated antigens and 240 Kd on melanoma cell line Ts294," <i>AACR</i> , 27:313, 1986.
	C100	Murray <i>et al.</i> , "Differential in vitro effects of recombinant alpha-interferon and recombinant gamma-interferon alone or in combination on the expression of melanoma-associated surface antigens," <i>J. Biol. Response Modifiers</i> , 7:152-161, 1988.
	C101	Nechushtan <i>et al.</i> , "Conformation of the Bax C-terminus regulates subcellular location and cell death," <i>EMBO Journal</i> , 18:2330-2341, 1999.
	C102	Nolan <i>et al.</i> , "Cloning and expression of a gene encoding gelonin, a ribosome-inactivating protein from <i>Gelonium multiflorum</i> ," <i>Gene</i> , 134:223-227, 1993.
	C103	Nuti <i>et al.</i> , "A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations," <i>Int. J. Cancer</i> , 29(5):539-546, 1982.
	C104	O'Boyle <i>et al.</i> , "Potentiation of antiproliferative effects of monoclonal antibody 1Ym-1 and immunoconjugate Lym-1-gelonin on human Burkitt's lymphoma cells with γ -interferon and tumor necrosis factor," <i>Journal of Immunotherapy</i> , 18:221-230, 1995.
	C105	O'Hare <i>et al.</i> , "Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence," <i>FEBS Lett.</i> , 273:200-204, 1990.
	C106	Owens and Young, "The genetic engineering of monoclonal antibodies," <i>Journal of Immunological Methods</i> , 168:149-165, 1994.
	C107	Ozawa <i>et al.</i> , "Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor," <i>Int. J. Cancer</i> , 43:152-157, 1989.
	C108	Pagliaro <i>et al.</i> , "Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity," <i>Clin. Cancer Res.</i> , 4(8):1971-1976, 1998.
	C109	Pai and Pastan "Immunotoxin therapy for cancer," <i>JAMA</i> , 269:78-81, 1993.
	C110	Panchagnula <i>et al.</i> , "Monoclonal antibodies in drug targeting," <i>Journal of Clinical Pharmacy & Therapeutics</i> , 22:7-19, 1997.
	C111	Panchal, "Novel Therapeutic Strategies to Selectively Kill Cancer Cells; Biochemical Pharmacology," 55:247-252, 1998.

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C112	Pastan <i>et al.</i> , "Recombinant toxins for cancer treatment," <i>Science</i> , 254:1173-1177, 1991.
	C113	Pearson <i>et al.</i> , "Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon," <i>Cancer Res.</i> 50:6379-6388, 1990.
	C114	Peterson and Krohn, "Mapping of B cell epitopes on steroid 17 α -hydroxylase, and autoantigen in autoimmune polyglandular syndrome type I," <i>Clin. Exp. Immunol.</i> , 98:104-109, 1994.
	C115	Porter, "Human immune response to recombinant human proteins," <i>J. Pharmaceutical Sciences</i> , 90:1-11, 2001.
	C116	Pullyblank and Monson, "Monoclonal antibody treatment of colorectal cancer," <i>British Journal of Surgery</i> , 84:1511-1517, 1997.
	C117	Ramakrishnan and Houston, "Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors: pokeweed antiviral protein or ricin A chain," <i>Cancer Res.</i> , 44(4):1398-404, 1984.
	C118	Reimann <i>et al.</i> , "In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. IV. Cytotoxic effect of an anti-T11-gelonin immunotoxin," <i>J. Clin. Invest.</i> , 82:129-138, 1988.
	C119	Rissoan <i>et al.</i> , "Subtractive hybridization reveals the expression of immunoglobulinlike transcript 7, Eph-B1, granzyme B and 3 novel transcripts in human plasmacytoid dendritic cells," <i>Blood</i> , 100(9):3295-3303, 2002.
	C120	Roselli <i>et al.</i> , "Clinical value of radiolabeled monoclonal antibodies in the management of carcinoma patients," <i>In Vivo</i> , 7:615-622, 1993.
	C121	Rosenblum <i>et al.</i> , "Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin," <i>Cancer Chemotherapy and Pharmacology</i> , 44:343-348, 1999.
	C122	Rosenblum <i>et al.</i> , "A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin," <i>Mol. Biother.</i> 3:6-13, 1991.
	C123	Rosenblum <i>et al.</i> , "A gelonin-containing immunotoxin directed against human breast carcinoma," <i>Mol. Biother.</i> 4:122-129, 1992.

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 4</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C124	Rosenblum <i>et al.</i> , "Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from <i>Gelonium multiflorum</i> ," <i>J Interferon Cytokine Res.</i> , 15(6):547-555, 1995.
	C125	Rosenblum <i>et al.</i> , "Antibody-mediated delivery of tumor necrosis factor (TNF- α)," <i>Proc. Am Cancer Res.</i> , 30:410, #1522, 1987.
	C126	Rosenblum <i>et al.</i> , "Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance," <i>Cancer Commun.</i> 3:21-27, 1991.
	C127	Rosenblum <i>et al.</i> , "Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity," <i>Interferon Res.</i> , 10:141-151, 1990.
	C128	Rosenblum <i>et al.</i> , "Monoclonal Antibodies for delivery of cytokines," <i>Cancer Bull</i> , 46(1):34-39, 1994.
	C129	Rosenblum <i>et al.</i> , "An antimelanoma immunotoxin composed of antibody AMI-018 and the plant toxin gelonin," <i>Proc. Am. Assoc. Cancer Res. Annu. Meet.</i> , 29:427, #1700, 1988 (Abstract)
	C130	Rosenblum <i>et al.</i> , "Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in Xenograft models," <i>Clin Cancer Res</i> ; 5:865-874, 1999.
	C131	Rowlinson-Busza <i>et al.</i> , "Target delivery of biologic and other antineoplastic agents," <i>Current Opinion in Oncology</i> , 4:1142-1148, 1992.
	C132	Roy <i>et al.</i> , "Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells," <i>Blood</i> , 77:2404-2412, 1991.
	C133	Salmon and Liu "Effects of granulocyte-macrophage colony-stimulating factor on in vitro growth of human solid tumors," <i>J. Clin. Oncol.</i> , 7:1346-1350, 1989.
	C134	Salmon <i>et al.</i> , "Evaluation of an automated image analysis system for counting human tumor colonies," <i>Internat. J. Cell Cloning</i> , 2:142-160, 1984.
	C135	Salmon <i>et al.</i> , "Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs," <i>New Eng. J. Med.</i> , 298:1321-1327, 1978.

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 4</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C136	Schienberg <i>et al.</i> , "Monoclonal Antibody M195: A diagnostic marker for acute myelogenous leukemia," <i>Leukemia</i> , 3(6):440-445, 1989.
	C137	Scholz <i>et al.</i> , "Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts," <i>Eur. J. Cancer</i> , 26(8):901-905, 1990.
	C138	Scott <i>et al.</i> , "An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors," <i>J. Natl. Cancer Inst.</i> , 79:1163-1172, 1987.
	C139	Singh <i>et al.</i> , "Hormonotoxins. Preparation and characterization of ovine luteinizing hormone-gelonin conjugate," <i>J. Biol. Chem.</i> , 264(6):3089-3095, 1989.
	C140	Sivam <i>et al.</i> , "Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates," <i>Cancer Res.</i> , 47:3169-3173, 1987.
	C141	Smyth <i>et al.</i> , "Granzymes: exogenous proteinases that induce target cell apoptosis," <i>Immunology Today</i> , 16(4):202 - 206, 1995.
	C142	Soule <i>et al.</i> , "Membrane 126-kilodalton phosphoglycoprotein associated with human carcinomas identified by a hybridoma antibody to mammary carcinoma cells," <i>Proc. Natl. Acad. Sci. USA</i> , 80:1332-1336, 1983.
	C143	Spitler <i>et al.</i> , "Immunotoxin therapy of malignant melanoma," <i>Med Oncol Tumor Pharmacother.</i> , 3:147-152, 1986.
	C144	Spitler <i>et al.</i> , "Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin," <i>Cancer Res.</i> , 47:1717-1723, 1987.
	C145	Spitler <i>et al.</i> , "Therapy of metastatic malignant melanoma using XomaZyme Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin," <i>Nuc. Med. And Biol.s.</i> , 16:625-627, 1989.
	C146	Stirpe <i>et al.</i> , "Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A," <i>J. Biol. Chem.</i> , 255:6947-6953, 1980.
	C147	Tai <i>et al.</i> , "In Vivo Cytotoxicity of Ovarian Cancer Cells through Tumor-selective Expression of the BAX Gene," <i>Cancer Res.</i> , 59:2121-2126, 1999.

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 4</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C148	Tao <i>et al.</i> , "Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region," <i>J. Immunol.</i> , 143:2595-2601, 1989.
	C149	Tedder <i>et al.</i> , "Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system," <i>J. Immunol.</i> 137(4):1387-1391, 1986.
	C150	Thorpe <i>et al.</i> , "An immunotoxin composed of monoclonal anti-thy 1.1 antibody and a ribosome-inactivating protein from saponaria oddicinalis: potent antitumor effects in vitro and in vivo," <i>J. Natl. Cancer Inst.</i> 75(1):151-159, 1985.
	C151	Thorpe <i>et al.</i> , "Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome-inactivating protein, gelonin," <i>Eur. J. Biochem.</i> , 116:447-454, 1981.
	C152	Thorpe <i>et al.</i> , "Monoclonal antibodies: clinical and regulatory issues," <i>Trends Biotechnol.</i> 11:40-42, 1993.
	C153	Till <i>et al.</i> , "An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins," <i>Cancer Res.</i> 48:1119-1123, 1988.
	C154	Vitetta <i>et al.</i> , "Redesigning nature's poisons to create anti-tumor reagents," <i>Science</i> , 238:1098-1104, 1987.
	C155	Von Hoff, "Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development," <i>Cancer and Metastasis Reviews</i> , 7:357-371, 1988.
	C156	Wahl <i>et al.</i> , "Experimental radioimmunotherapy," <i>Cancer</i> , 73:989-992, 1994.
	C157	Waldenamn, "Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma," <i>J. Natl. Cancer Inst.</i> 81:914-923, 1989.
	C158	Waldmann <i>at al.</i> , "Monoclonal antibodies in diagnosis and therapy," <i>Science</i> , 252:1657-1662, 1991.
	C159	Wels <i>et al.</i> , "Diminution of antibodies directed against tumor cell surface epitopes: a single chain Fv fusion molecule specifically recognizes the extracellular domain of the c-erbB-2 receptor," <i>Journal of Steroid Biochemistry & Molecular Biology</i> , 43:1-7, 1992.
	C160	Williams <i>et al.</i> , "Targeting and therapy of human glioma xenografts in vivo utilizing radiolabeled antibodies," <i>Cancer Res.</i> 50:974s-979s, 1990.

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 4</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C161	Wool <i>et al.</i> , "Structure and evolution of mammalian ribosomal proteins," <i>Biochem Cell Biol.</i> , 73:933-947, 1995
	C162	Worn and Pluckthun, "Mutual stabilization of V _L and V _H in single-chain antibody fragments, investigated with mutants engineered for stability," <i>Biochemistry</i> ; 37:13120-13127, 1998.
	C163	Xu <i>et al.</i> , "Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice," <i>Leukemia</i> , 10:321-326, 1996.
	C164	Yeung <i>et al.</i> , "Trichosanthin, α -momorcharin and β -momorcharin: identity of aborifacient and ribosome-inactivating proteins," <i>Int. J. Pept. Protein Res.</i> , 31(3):265-8, 1988.
	C165	Yokota <i>et al.</i> , "Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin," <i>Cancer Res.</i> , 50:32-37, 1990.
	C166	Young, "Cell-Mediated Killing: A common Mechanism?" <i>Cell</i> , 46:641-642, 1986.
	C167	Yung <i>et al.</i> , "In vitro chemosensitivity testing and its clinical application in human gliomas," <i>Neurosurg. Rev.</i> , 12:197-203, 1989.
	C168	Zuckerman <i>et al.</i> , "Preparation and biological activity of recombinant leukocyte interferon A [rIFN alpha A] conjugated to an antimelanoma murine monoclonal antibody [ZME-018]," <i>Proc. Amer. Assoc. Cancer Res.</i> , 28:384, 1987.
	C169	Aboud-Pirak <i>et al.</i> , "Cytotoxic activity of daunorubicin or vindesine conjugated to a monoclonal antibody on cultured MCF-7 breast carcinoma cells," <i>Biochem. Pharmacol.</i> , 38:641-648, 1989.
	C170	Adams <i>et al.</i> , "The Bcl-2 Protein Family: Arbiters of Cell Survival," <i>Science</i> , 281:1322-1326, 1998.
	C171	Alfthan <i>et al.</i> , "Properties of single-chain antibody containing different linker peptides," <i>Protein Engineering</i> ; 8:725-731, 1995.
	C172	Alkan <i>et al.</i> , "Antiviral and antiproliferative effects of interferons delivered via monoclonal antibodies," <i>J. Interferon Res.</i> , 4(3):355-363, 1984.
	C173	Alley <i>et al.</i> , "Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay," <i>Cancer Res.</i> , 48:589-601, 1988.

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 4</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C174	Aqeilan <i>et al.</i> , "Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy," <i>FEBS Letters</i> , 457:271-276, 1999.
	C175	Arnon <i>et al.</i> , "Monoclonal antibodies for immunotargeting of drugs in cancer therapy," <i>Monoclonal Antibodies and Cancer Therapy</i> , Alan R. Liss, Inc. pp 243-256, 1985.
	C176	Atkinson <i>et al.</i> , "Conjugation of folate via gelonin carbohydrate residues retains ribosomal-activating properties of the toxin and permits targeting to folate receptor positive cells," <i>Biochem Molec. Biol.</i> , 276(30):27930-27935, 2001.
	C177	Barbieri and Stirpe, "Ribosome-inactivating proteins from plants: Properties and possible uses," <i>Cancer Surveys</i> , 1(3):489-520.
	C178	Batra <i>at al.</i> , "Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin," <i>Proc. Natl. Acad. Sci.</i> , 86:8545-8549, 1989.
	C179	Batra <i>at al.</i> , "Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv)," <i>Mol. Cell. Biol.</i> 11:2200-2205, 1991.
	C180	Bendig, "Humanization of rodent monoclonal antibodies by CDR grafting," <i>METHODS: A Companion to Methods in Enzymology</i> , 8:83-93, 1995.
	C181	Berkower, "The promise and pitfalls of monoclonal antibody therapeutics," <i>Current Opinion in Biotechnology</i> , 7:622-628, 1996.
	C182	Bird <i>et al.</i> , "Single-chain antigen-binding proteins," <i>Science</i> , 242:423-426, 1988.
	C183	Bjorn <i>et al.</i> , "Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins," <i>Cancer Res.</i> , 45:1214-1221, 1985.
	C184	Blair <i>et al.</i> , "Linkage of cytotoxic agents to immunoglobulins," <i>J. Immunol. Methods</i> , 59:129-143, 1983.
	C185	Blakey <i>et al.</i> , "Antibody toxin conjugates: a perspective," <i>Monoclonal Antibody Therapy</i> . Waldmann (ed). 45:50-90, 1988.

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.